Results 21 to 30 of about 23,621 (250)
YAP1 Meets Tumor Suppression [PDF]
Molecular Cell, 2007 In this issue of Molecular Cell, Matallanas et al. (2007) demonstrate that RASSF1A-induced apoptosis impinges on the transcriptional coactivator YAP1, whose nuclear translocation and binding to p73 result in proper execution of the cell death pathway. Indeed, RASSF1A silencing in tumors inhibits YAP1-p73-dependent apoptosis.
Strano, Sabrina, Blandino, Giovanni
openaire +2 more sources
Cells, 2020 Background: Tumor-associated macrophages (TAMs) constitute a major portion of the leukocyte infiltrate found in breast cancer (BC). BC cells may reprogram TAMs in a pro-angiogenic and immunosuppressive sense.
Sara Donzelli +8 more
doaj +1 more source
The feedback loop of ANKHD1/lncRNA MALAT1/YAP1 strengthens the radioresistance of CRC by activating YAP1/AKT signaling [PDF]
Cell Death & Disease, 2022 AbstractInnate radioresistance substantially limits the effectiveness of radiotherapy for colorectal cancer (CRC); thus, a strategy to enhance the radiosensitivity of CRC is urgently needed. Herein, we reported that ankyrin repeat and KH domain containing 1 (ANKHD1) serves as a key regulator of radioresistance in CRC. ANKHD1 was highly expressed in CRC
Ping-an Yao +5 more
openaire +3 more sources
PSME4 Degrades Acetylated YAP1 in the Nucleus of Mesenchymal Stem Cells
Pharmaceutics, 2022 Intensive research has focused on minimizing the infarct area and stimulating endogenous regeneration after myocardial infarction. Our group previously elucidated that apicidin, a histone deacetylase (HDAC) inhibitor, robustly accelerates the cardiac ...
Yong Sook Kim +10 more
doaj +1 more source
Neoplasia: An International Journal for Oncology Research, 2021 Increased expression of Yes-associated protein-1 (YAP1) was shown to correlate with reduced survival in breast cancer (BC) patients. However, the exact mechanism of YAP1 regulation in BC cells remains ambiguous.
Jibran Sualeh Muhammad +9 more
doaj +1 more source
Cell Death and Disease, 2021 Chondrosarcoma (CHS) is the second most common bone malignancy with limited therapeutic approaches. Our previous study has found that Yes associated protein 1 (YAP1) is downregulated in CHS cells treated with bromodomain and extraterminal domain (BET ...
Huan-Tian Zhang +15 more
doaj +1 more source
GPSM2 Promotes Pancreatic Cancer Progression Through METTL3-Mediated m6A Modification of YAP1 mRNA. [PDF]
J Cell Mol MedABSTRACT Pancreatic cancer poses a major therapeutic challenge due to its insidious onset and difficulty in early diagnosis. G‐protein signalling modulator 2 (GPSM2), a member of the G‐protein signalling regulator family, is highly expressed in various tumour tissues; however, its role in pancreatic cancer remains largely undefined.
Xiu J +9 more
europepmc +2 more sources
Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
Molecular Oncology, 2020 Hippo/YAP1 signaling is a major regulator of organ size, cancer stemness, and aggressive phenotype. Thus, targeting YAP1 may provide a novel therapeutic strategy for tumors with high YAP1 expression in esophageal cancer (EC).
Shumei Song +14 more
doaj +1 more source
One way to rule them all: G2/M gene regulation by oncogenic YAP1 and B-MYB
Molecular & Cellular Oncology, 2019 The Hippo pathway plays a major role in regulating organ size during embryogenesis. Loss of Hippo signaling can cause cancer due to unrestricted cell proliferation.
Grit Weinstock, Stefan Gaubatz
doaj +1 more source
Genome-wide CRISPR screening reveals novel therapeutic targets in RIT1-driven lung cancer
Molecular & Cellular Oncology, 2021 In recent work, we performed CRISPR/Cas9 screening in RIT1 (Ras-like in all tissues)-mutant cancer cells. We found that RIT1-mutant cells are vulnerable to loss of mitotic regulators, and mutant RIT1 synergizes with YAP1 (yes-associated protein 1) in ...
Amanda K. Riley, Alice H. Berger
doaj +1 more source